Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7633350 | 0.88 | GLRA1 (0.32) | TERT | |
| SCHEMBL7872934 | 0.87 | — | — | |
| SCHEMBL6841493 | 0.81 | GLRA1 (0.30) | — | |
| SCHEMBL1493219 | 0.80 | GLRA1 (0.38) | — | |
| SCHEMBL4734227 | 0.79 | TERT (0.31) | TERT | |
| SCHEMBL27606643 | 0.77 | MEN1 (0.31) | — | |
| SCHEMBL11764044 | 0.74 | — | — | |
| SCHEMBL24065976 | 0.74 | MVD (0.36) | TERT | |
| SCHEMBL3379494 | 0.74 | GLRA1 (0.32) | TERT | |
| SCHEMBL468872 | 0.72 | PAOX (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2301962-B1 | Invention affecting GLP-1 and Exendin | UNIV MARBURG PHILIPPS (DE) | 2013-10-30 | — | — | EP | claimed |
| EP-2070946-B1 | Invention affecting GLP-1 and Exendin | UNIV MARBURG PHILIPPS (DE) | 2013-05-29 | — | — | EP | claimed |
| US-20130095037-A1 | PEPTIDE DERIVATIVES OF EXENDIN-4 | PHILIPPS-UNIVERSITAT MARBURG (DE) | 2013-04-18 | — | — | US | claimed |
| US-8268781-B2 | Peptide derivatives of exendin-4 | PHILIPPS-UNIVERSITAT MARBURG (DE) | 2012-09-18 | — | — | US | claimed |
| US-20090180953-A1 | Invention concerning GLP-1 and exendin | PHILIPPS-UNIVERSITAT MARBURG (DE) | 2009-07-16 | — | — | US | claimed |
| EP-1784422-A2 | GLP-1 AND EXENDIN RELATED INVENTION | Philipps-Universität Marburg (DE) | 2007-05-16 | — | — | EP | claimed |
| WO-2006024275-A2 | GLP-1 AND EXENDIN RELATED INVENTION | PHILIPPS-UNIVERSITÄT MARBURG (DE) | 2006-03-09 | — | — | WO | claimed |
| EP-4556029-A2 | RADIOPHARMACEUTICAL CONJUGATE | The South African Nuclear Energy Corporation Limited (ZA) | 2025-05-21 | — | — | EP | disclosed |
| CN-107106709-B | Radiopharmaceutical conjugates comprising a metabolite and an EPR agent targeting tumor cells | 南非核能源有限公司 | 2021-04-06 | — | — | CN | disclosed |
| US-10874753-B2 | Radiopharmaceutical conjugate of a metabolite and an EPR agent, for targeting tumour cells | THE SOUTH AFRICAN NUCLEAR ENERGY CORPORATION LIMITED (ZA) | 2020-12-29 | — | — | US | disclosed |
| US-20170296684-A1 | RADIOPHARMACEUTICAL CONJUGATE | UNIVERSITY OF CAPE TOWN (ZA) | 2017-10-19 | — | — | US | disclosed |
| EP-3197504-A2 | RADIOPHARMACEUTICAL CONJUGATE OF A METABOLITE AND AN EPR AGENT, FOR TARGETING TUMOUR CELLS | The South African Nuclear Energy Corporation Limited (ZA) | 2017-08-02 | — | — | EP | disclosed |
| WO-2016046793-A2 | RADIOPHARMACEUTICAL CONJUGATE | THE SOUTH AFRICAN NUCLEAR ENERGY CORPORATION LIMITED (ZA) | 2016-03-31 | — | — | WO | disclosed |
| US-20090180953-A1 | Invention concerning GLP-1 and exendin | PHILIPPS-UNIVERSITAT MARBURG (DE) | 2009-07-16 | — | — | US | disclosed |
| EP-2070946-A2 | Invention affecting GLP-1 and Exendin | Philipps-Universität Marburg (DE) | 2009-06-17 | — | — | EP | disclosed |
| EP-1784422-A2 | GLP-1 AND EXENDIN RELATED INVENTION | Philipps-Universität Marburg (DE) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006024275-A2 | GLP-1 AND EXENDIN RELATED INVENTION | PHILIPPS-UNIVERSITÄT MARBURG (DE) | 2006-03-09 | — | — | WO | disclosed |
| EP-0963182-A4 | METHOD OF TREATING A DISEASE PROCESS IN A LUMINAL STRUCTURE | UNIV COLUMBIA (US) | 2000-10-18 | — | — | EP | disclosed |
| EP-0963182-A1 | METHOD OF TREATING A DISEASE PROCESS IN A LUMINAL STRUCTURE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1999-12-15 | — | — | EP | disclosed |
| WO-1998012979-A1 | METHOD OF TREATING A DISEASE PROCESS IN A LUMINAL STRUCTURE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1998-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874753-B2 | Radiopharmaceutical conjugate of a metabolite and an EPR agent, for targeting tumour cells | EPRS1, FOLH1, SLC46A1 | TERT 2273/4885 |
| US-20170296684-A1 | RADIOPHARMACEUTICAL CONJUGATE | FOLH1, EPRS1, FOLR1 | TERT 2851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.